{"ticker": {"uuid": "7c7d28e1-1b9e-4d21-84bb-7a04900c2d63", "symbol": "DWTX", "name": "Dogwood Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to sales forward of Dogwood Therapeutics, Inc. \u2013 NASDAQ:DWTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNbHpwRGRnMFl3MW5WTFpPZTNZTjFRaXlFN2xfN2pfbENXLVUwbEtlY0pxSmJBNnd6REg0MldBMG1kd29va2FJbzVRN1V5V2FLaEJQVjdpcE5ENDZrc3J1cHhUUHE5LWNRUl9ZanZENHBzQmdxYy1ibjJ2M1JOU0Y3aktOTFNMTS1Jc3A2NUlkUk1xaDhobGtJNENZU0Rodw?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T19:08:54+00:00", "published_display": "06 Jul 2026 19:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dogwood-therapeutics-appoints-iain-dukes-124500033.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:45:00+00:00", "published_display": "30 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood taps OrbiMed's Iain Dukes to guide pain drug pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZVJjSmxySjRwZk1DMzdlaVVfbi1EUEpUTEhwSTFFeG04TFZwd0lqWW9SNFh3Mllzbnl5Qk1aczRnTXF5djZqbGVBalFNb3o0dk94cmNFelNxTk9KSUI5Yml0TnB0NDRJaXBCcGxRMTE1TlVOQzE2SzlVTnBZcWRMRmJqN2RfclV6enpTOFB0cmFRczVyRXlvekJIZG9OcUtHUGFaY3pPbkxEdEtnYkFMSmxmQjN3czdxSGRvUWR6bk8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Dogwood Therapeutics' (NASDAQ:DWTX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell 3000E Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPbGctN2J4aWJFY2pXMFBIX3QwLTdUd2R3ZjB6ZFVmdjdSbld6VXFUcmN4WFBIS3hxMHRYQnBQbHBrLU9vNDczOGRvYmRDV1dzMzJzMy0zQlk5M1RhMkNFTVZramJST3JvTW5EZzVEYzU2bHdyZGMtSm16YW1mU3M3RnExY0lUc0IxZlhMZGFFN0NhWEJYVnhhc3NZVi02dWVNOVZQNVVjVzNKcDlXbE5sbzkzLTNBbFlTaXkwWQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: EPS Beat Driven by Cost Discipline Despite No Revenue - EBITDA Estimate Trend", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNcDc4VHQ0TF9XYWRWUXczYXgxendId3hpWHQycGc5bEpiYWlVaWJ4SkxQZkJodjlqeUQxbUpEQ1lBZ2V6NFoxdi1VdGJMcUJiWlBiNFM2SVpkLTRXQ204LS1mQnpvZHgxQzRQUV9uQjRoUjVpQnctbHBnei00QXQ4cDlOa1Rpckd2dHQya1NaR3Ywd2EtM3UyNjQ5UDMxUklrY21QUERPMmRsbmZLMUFrNHRqUnJBd1dMTkd0ampzMHVPZVhrV3ZOYnN1RmdsMzRpN3BuYmVNZE1XY1o4YVlFZ0xB?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Dogwood Therapeutics, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQOE93VzhuLThyOTlmTlJGc3I0Zk15V3BnSzVvT2Y3NmhxbE0yYy1FUW05MVl1TnZkWm1FWVlYWEk0NHJHU1A2UG9qd1BZVGt5cGV6T0xYMmVDSXBXVHhYVWJjcG9Ta1BCeUw0eXQ5NmZwdGdIS3c5NlZQa1hqNENhUTUyOGZDV29OT2J3NXVhLVpWNnN5OHdQZ1ZhT0JZc19qY3Z0Rk5fTVNIeUl5ODJ0cUU5UXJvdmN3QUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics (DWTX) investors approve share increase and annual Say-on-Pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPenlJVHBJZVNfdVF4Z2Z0NHQ0MjNRQmJQbzZaOWp5UUp5a1Baa1hhRzJMN1NtTUJQMWtCQ2hLOW9xZmxSRVR5Y1JHS0dhOFh3R0pncDBPeFBsNnFrTlIxaWJHSG5yZENRT3ZrTDFwa1NJV0ttNEV6TE5sYjcteTJ1MDFocmVuYnl4eGpxYXNSeTJMT1NNQkJTRG9OUFlXUXg4QlV3Zy1naVdVTXk2bU1nTy1tZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDGAR Filing Documents for 0001558370-24-013167", "summary": "This article provides details of an EDGAR Form 8-K filing (SEC Accession No. 0001558370-24-013167) filed by Virios Therapeutics, Inc. The filing date was October 7, 2024, with a period of report ending October 4, 2024. It covers various items, including material definitive agreem", "url": "https://www.sec.gov/Archives/edgar/data/1818844/0001558370-24-013167-index.htm", "source_name": "SEC.gov", "published_at": "2026-06-06T13:40:48", "published_display": "06 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DWTX - Dogwood Therapeutics Inc Stock Price and Quote", "summary": "This page provides a detailed stock quote and company information for Dogwood Therapeutics Inc (DWTX), including its current stock price, financial metrics, insider and institutional ownership, and recent performance. It also lists significant news events and announcements relate", "url": "https://finviz.com/stock?t=DWTX", "source_name": "Finviz", "published_at": "2026-06-01T23:39:14", "published_display": "01 Jun 2026 23:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Inc. (DWTX) Rises 1.2% as Stock Holds Above Key Support - Volume Breadth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSzlRNGhlOGJXTkxIQzV2eEpBRWxmZG9Fd3BqUWs2Z0lPOXctWW5zQnZlTEhFd3hGbnBCZnVZT2phTFNNMHV3MHJPcWpCenZLZXUwSm5pMWhjWTRSeEhHdWxna0ZKTURjb1ZYZjBKdFh3X0FER3V6WXUxNjluWDFONk93UGtUNmY2MUpfdXJrVmotWXJidVloSlRyVDdVZVpSbmpCVFYzQVBxLTR2UkRlSUw5OE54QUtPSlE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Commencement of Halneuron\u00ae Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-announces-commencement-halneuron-124500058.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:45:00+00:00", "published_display": "18 May 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dogwood Therapeutics Announces First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-announces-first-quarter-123000365.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DOGWOOD THERAPEUTICS ($DWTX) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOemVoM1doa2tCRWk3UElHRXpqWmpxR25vY0cxWnQxMGF4bFhkeFVXc0RzX3hFR1piazRZWGFTQ2tlOUQ5YnlLT1lBc2ZCdkg4OVlaMXBtSF9wbzdxbFpOZ0RFQzA4ck9FS2l1RzlCdjNYUUhtZGw5Wi1VcUlRQWhPSl8zTVF6ZWZuV2VRVVZuNHRhX1EyWUZXVg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-report-first-quarter-123000051.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T12:30:00+00:00", "published_display": "07 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pain-drug developer Dogwood sets May 14 earnings release", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUkJGZjlhZWh3QzFyeWZYZElhR0JfWjlyVW9ZYU5BWUd6QVNCUVdzT1QycVZvNzFPNFladkNKM3FFOXhhc3RrMUVhZkNHWHdrelNyMFJIaHVybUlDelZqYmphTmZLSU1tTDB4RGxzelVfTEN1OXI5QWdtMlBNTGhXMUk5R09FMlJMOEFkZkFQSmZRNVU4R085LV9zcmVYVTBxenBmeEo1dXVnQnJhQXR1a1RqdFVrNkhZdHk3VjZpYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-announces-worldwide-development-130000827.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T13:00:00+00:00", "published_display": "23 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Worldwide Development and", "summary": "Dogwood Therapeutics has announced a global development and commercialization partnership with PRIDCor Therapeutics for its anti-viral candidates, IMC-1 and IMC-2, with potential payments of up to $100 million. This agreement allows Dogwood to shift its focus to its lead pain and", "url": "https://www.globenewswire.com/news-release/2026/04/23/3279991/0/en/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-assets-with-potential-value-up-to-100m.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T09:00:00", "published_display": "23 Apr 2026 09:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPaDNzUnR0ZDJkQ3JXWktWLS05ZmZRMXBNQ1NSRjlfN1IwRXNhbzJmS1dveWVXYVhzX2FOTXBfVVNzSXBhb0VYcmhMM3Flc2xBSHJKWThianlZYUdjWXJlWnFMUFhpa01jcWxHRW94RWp3R2F5aHROZzhmaHlwdllnVXpuS0g2OWN0YnNNVDluQ0xyTkdoZGY5NDFvN3kzQ29mQnc3aFhnWHgyZ1ZJYXJBUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSGcxQ2t2MTgwV0ZHUWlZc193anZZQnZqZ21VaUp2TnBkZ2hSdWtWQi1fVkVkNlNTQ1lmakhTWVBhTFhNXzdNY0plOHlPWW9HQWcwODFFLTFsMTZvdmlaUzd6T2ctc0dQZEdLSmlaamw3N0xLQlFWQTg0R1FiT2VyaEo1ZWRwdUZ3SE52ZTl3a2kwRHBkQUphOFVqZnZkdTkxLWhiSVhRektIRzQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "DWTX - Dogwood Therapeutics Latest Stock News & Market Updates", "summary": "This page provides comprehensive news and analysis for Dogwood Therapeutics (DWTX), a biopharmaceutical company focused on pain and neuropathy treatments. Key updates include the dosing of the first patient in a Phase 2b trial for Halneuron\u00ae for chemotherapy-induced neuropathic p", "url": "https://www.stocktitan.net/news/DWTX/page-3.html", "source_name": "Stock Titan", "published_at": "2026-02-25T18:51:12", "published_display": "25 Feb 2026 18:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics, Inc. Announces Financing of up to", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxQa053d29PUVR5TUVwaDNOOEJaU2xzUkU2UmZkLXIxeHNyMWJCRndlU3VleGllUEl0R3pyMG1QaVprSjVqdndJR1pFUGtaY1Y5Y2ZvLTZ5RWVySzhnUFNEOFpmMEFpOUpaOXBXWUF5Mi0xQXVqQmR4VF9vUlZaTXg3REpkekk3VUZ2d3hOUlRGLThGWXlaUVJVSHg1bmtuM3dPQWxxdWtiSW4wZlRYNDdaOGhpSjVEclExeVFpX2JXVlZkMGRXMHhkTUZsQnU4ZlJyRk0wRUlHUUJLR3M3a1RtY3JoNHMzdUJBemlseTlPS2FJZmh3ZlhfdFIwekh6U0RlcjUxTnMwdkdjMU1JdGZndW05NWN6eTV4?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain", "summary": "Dogwood Therapeutics, Inc. today announced positive interim results from its Halneuron\u00ae Phase 2b clinical trial for chemotherapy-induced neuropathic pain (CINP). The interim analysis of 97 patients showed that Halneuron\u00ae treated patients demonstrated separation from placebo in pa", "url": "https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/dogwood-therapeutics-announces-positive-interim-phase-2b-clinical-trial-results-in-chemotherapy-induced-neuropathic-pain.html", "source_name": "GlobeNewswire", "published_at": "2025-12-22T10:15:00", "published_display": "22 Dec 2025 10:15", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Reports Third Quarter 2025 Financial Results", "summary": "Dogwood Therapeutics reported its third-quarter 2025 financial results, highlighting significant progress in its clinical trials and pipeline development. The company has enrolled 100 patients in its Halneuron\u00ae Phase 2b trial and secured an exclusive worldwide license for SP16, a", "url": "https://www.globenewswire.com/news-release/2025/11/06/3182625/0/en/Dogwood-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html", "source_name": "GlobeNewswire", "published_at": "2025-11-06T08:45:00", "published_display": "06 Nov 2025 08:45", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics, Inc. (DWTX) Investor Call Presentation - Slideshow (NASDAQ:DWTX) 202", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNT0JWWkd5OG1tLTd0bGh3XzFOUE5mb3Z3V2l6YkdEa2llb0d2SF9tSVZJZTJtNlZhQ3BjN29kNDlPOXQ4MmdGZFpQY2xFX1BERnRpY1VSdEZDbmg5T1FEY2JibEJwYkRqemZfeTVJZXdEX1V5eF9sRDRQa2hKWDdUSk41S3Bhc3RLcFRncmlzcmp4VkhkajhMVw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIRI SEC Filings - Virios Therapeutics, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for Virios Therapeutics (VIRI) and its successor, Dogwood Therapeutics (DWTX), after a business combination with Wex Pharmaceuticals in October 2024. It includes 10-K, 10-Q, 8-K, and Form 4 filings, featuring AI-powered summaries and real-", "url": "https://www.stocktitan.net/sec-filings/VIRI/", "source_name": "Stock Titan", "published_at": "2025-08-13T03:10:34", "published_display": "13 Aug 2025 03:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron\u00ae Phase 2b Trial", "summary": "Dogwood Therapeutics announced the enrollment of the first 50 patients in its ongoing Halneuron\u00ae Phase 2b trial for Chemotherapy-Induced Neuropathic Pain (CINP). The company expects interim data readout for approximately 100 patients in Q4 2025 and plans to release full results i", "url": "https://www.globenewswire.com/news-release/2025/08/07/3129514/0/en/Dogwood-Therapeutics-Announces-Enrollment-of-First-Fifty-Patients-in-Ongoing-Halneuron-Phase-2b-Trial.html", "source_name": "GlobeNewswire", "published_at": "2025-08-07T13:08:00", "published_display": "07 Aug 2025 13:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DWTX Stock: Price, Forecast, Financials & AI Analysis", "summary": "Dogwood Therapeutics, Inc. (DWTX) is a biopharmaceutical company focused on developing therapies for pain and fatigue-related disorders, including a non-opioid analgesic program with Halneuron for cancer pain and an antiviral program. The company has seen significant clinical pro", "url": "https://intellectia.ai/stock/DWTX", "source_name": "Intellectia AI", "published_at": "2025-01-27T09:39:26", "published_display": "27 Jan 2025 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth", "summary": "Virios Therapeutics Llc (DWTX) stock reached a 52-week high of $15.74, showing strong momentum with over 45% growth in the past week, despite being considered overvalued by InvestingPro's Fair Value analysis. The company is facing potential Nasdaq delisting due to low stockholder", "url": "https://www.investing.com/news/company-news/dwtx-stock-hits-52week-high-at-1574-amidst-strong-yearly-growth-93CH-3827837", "source_name": "Investing.com", "published_at": "2025-01-23T12:42:00", "published_display": "23 Jan 2025 12:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement", "summary": "Dogwood Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the listing compliance matter. This news comes as the company anticipates top-line results from its Phase 2a study of IMC-2 for Long-COVID in mid-November 2024 and", "url": "https://www.globenewswire.com/news-release/2024/10/30/2971771/0/en/dogwood-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement.html", "source_name": "GlobeNewswire", "published_at": "2024-10-30T21:39:37", "published_display": "30 Oct 2024 21:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics (DWTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5MUFRfQi11U0xldzg3bXR3WDNieF9IQ1JCZnBVY21KVlItSEl5Mjhnb3A3MmRDRHg1cVNseG5fMTRhY0dpd1FRay1tQ1N2aUdfSm9famdrbXQyQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-10-12T15:21:14+00:00", "published_display": "12 Oct 2024 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors wooed for new analgesic", "summary": "CK Life Sciences is seeking new investors for the continued development of its analgesic drug, Halneuron, following a merger of its biotech subsidiary Wex Pharmaceuticals with US-listed Virios Therapeutics. The new entity, Dogwood Therapeutics, aims to secure incremental funding ", "url": "https://www.thestandard.com.hk/finance/article/66798/Investors-wooed-for-new-analgesic", "source_name": "The Standard (HK)", "published_at": "2024-10-09T11:10:45", "published_display": "09 Oct 2024 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CK Life unit to merge with Nasdaq biotech", "summary": "CK Life Sciences International announced that its wholly-owned subsidiary will merge with Nasdaq-listed Virios Therapeutics. The combined entity, to be renamed Dogwood Therapeutics, will remain listed on Nasdaq. This strategic move involves CK Life selling Pharmagesic to Virios f", "url": "https://www.thestandard.com.hk/finance/article/66751/CK-Life-unit-to-merge-with-Nasdaq-biotech", "source_name": "The Standard (HK)", "published_at": "2024-10-08T11:41:44", "published_display": "08 Oct 2024 11:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics Transforms into Dogwood Therapeutics", "summary": "Virios Therapeutics has announced its merger with Pharmagesic, a subsidiary of Sealbond Limited, resulting in the formation of Dogwood Therapeutics, Inc. The newly branded company will focus on developing non-opioid pain treatments and antiviral drugs for long-term health conditi", "url": "https://finance.yahoo.com/news/virios-therapeutics-transforms-dogwood-therapeutics-122907415.html", "source_name": "Market source", "published_at": "2024-10-08T03:51:57", "published_display": "08 Oct 2024 03:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics And Wex Pharmaceuticals To Merge", "summary": "Virios Therapeutics and Wex Pharmaceuticals have announced a definitive share exchange agreement to merge in an all-stock transaction, forming Dogwood Therapeutics, Inc. (NASDAQ: DWTX). The combined company will focus on developing three assets: Halneuron\u00ae for chemotherapy-induce", "url": "https://www.citybiz.co/article/609380/virios-therapeutics-and-wex-pharmaceuticals-to-merge/", "source_name": "citybiz", "published_at": "2024-10-07T22:09:34", "published_display": "07 Oct 2024 22:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: \u201cDWTX\u201d)", "summary": "Virios Therapeutics and Wex Pharmaceuticals have announced a business combination to form Dogwood Therapeutics, Inc. (NASDAQ: DWTX). This new company will focus on developing three assets: Halneuron\u00ae for chemotherapy-induced neuropathic pain, IMC-1 for fibromyalgia, and IMC-2 for", "url": "https://finance.yahoo.com/news/virios-therapeutics-inc-wex-pharmaceuticals-110500914.html", "source_name": "Market source", "published_at": "2024-10-07T17:27:32", "published_display": "07 Oct 2024 17:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc.", "summary": "Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. are combining to form Dogwood Therapeutics, Inc. (Nasdaq: DWTX), focusing on developing treatments for chemotherapy-induced neuropathic pain, fibromyalgia, and Long-COVID. The new company secured $19.5 million in financing a", "url": "https://www.globenewswire.com/news-release/2024/10/07/2958810/0/en/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-announce-business-combination-to-form-dogwood-therapeutics-inc-nasdaq-dwtx.html", "source_name": "GlobeNewswire", "published_at": "2024-10-07T07:05:00", "published_display": "07 Oct 2024 07:05", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to sales forward of Dogwood Therapeutics, Inc. \u2013 NASDAQ:DWTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNbHpwRGRnMFl3MW5WTFpPZTNZTjFRaXlFN2xfN2pfbENXLVUwbEtlY0pxSmJBNnd6REg0MldBMG1kd29va2FJbzVRN1V5V2FLaEJQVjdpcE5ENDZrc3J1cHhUUHE5LWNRUl9ZanZENHBzQmdxYy1ibjJ2M1JOU0Y3aktOTFNMTS1Jc3A2NUlkUk1xaDhobGtJNENZU0Rodw?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T19:08:54+00:00", "published_display": "06 Jul 2026 19:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dogwood-therapeutics-appoints-iain-dukes-124500033.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T12:45:00+00:00", "published_display": "30 Jun 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood taps OrbiMed's Iain Dukes to guide pain drug pipeline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZVJjSmxySjRwZk1DMzdlaVVfbi1EUEpUTEhwSTFFeG04TFZwd0lqWW9SNFh3Mllzbnl5Qk1aczRnTXF5djZqbGVBalFNb3o0dk94cmNFelNxTk9KSUI5Yml0TnB0NDRJaXBCcGxRMTE1TlVOQzE2SzlVTnBZcWRMRmJqN2RfclV6enpTOFB0cmFRczVyRXlvekJIZG9OcUtHUGFaY3pPbkxEdEtnYkFMSmxmQjN3czdxSGRvUWR6bk8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Dogwood Therapeutics' (NASDAQ:DWTX) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell 3000E Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPbGctN2J4aWJFY2pXMFBIX3QwLTdUd2R3ZjB6ZFVmdjdSbld6VXFUcmN4WFBIS3hxMHRYQnBQbHBrLU9vNDczOGRvYmRDV1dzMzJzMy0zQlk5M1RhMkNFTVZramJST3JvTW5EZzVEYzU2bHdyZGMtSm16YW1mU3M3RnExY0lUc0IxZlhMZGFFN0NhWEJYVnhhc3NZVi02dWVNOVZQNVVjVzNKcDlXbE5sbzkzLTNBbFlTaXkwWQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: EPS Beat Driven by Cost Discipline Despite No Revenue - EBITDA Estimate Trend", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNcDc4VHQ0TF9XYWRWUXczYXgxendId3hpWHQycGc5bEpiYWlVaWJ4SkxQZkJodjlqeUQxbUpEQ1lBZ2V6NFoxdi1VdGJMcUJiWlBiNFM2SVpkLTRXQ204LS1mQnpvZHgxQzRQUV9uQjRoUjVpQnctbHBnei00QXQ4cDlOa1Rpckd2dHQya1NaR3Ywd2EtM3UyNjQ5UDMxUklrY21QUERPMmRsbmZLMUFrNHRqUnJBd1dMTkd0ampzMHVPZVhrV3ZOYnN1RmdsMzRpN3BuYmVNZE1XY1o4YVlFZ0xB?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Dogwood Therapeutics, Inc. Insider Trading Activity", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQOE93VzhuLThyOTlmTlJGc3I0Zk15V3BnSzVvT2Y3NmhxbE0yYy1FUW05MVl1TnZkWm1FWVlYWEk0NHJHU1A2UG9qd1BZVGt5cGV6T0xYMmVDSXBXVHhYVWJjcG9Ta1BCeUw0eXQ5NmZwdGdIS3c5NlZQa1hqNENhUTUyOGZDV29OT2J3NXVhLVpWNnN5OHdQZ1ZhT0JZc19qY3Z0Rk5fTVNIeUl5ODJ0cUU5UXJvdmN3QUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics (DWTX) investors approve share increase and annual Say-on-Pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPenlJVHBJZVNfdVF4Z2Z0NHQ0MjNRQmJQbzZaOWp5UUp5a1Baa1hhRzJMN1NtTUJQMWtCQ2hLOW9xZmxSRVR5Y1JHS0dhOFh3R0pncDBPeFBsNnFrTlIxaWJHSG5yZENRT3ZrTDFwa1NJV0ttNEV6TE5sYjcteTJ1MDFocmVuYnl4eGpxYXNSeTJMT1NNQkJTRG9OUFlXUXg4QlV3Zy1naVdVTXk2bU1nTy1tZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDGAR Filing Documents for 0001558370-24-013167", "summary": "This article provides details of an EDGAR Form 8-K filing (SEC Accession No. 0001558370-24-013167) filed by Virios Therapeutics, Inc. The filing date was October 7, 2024, with a period of report ending October 4, 2024. It covers various items, including material definitive agreem", "url": "https://www.sec.gov/Archives/edgar/data/1818844/0001558370-24-013167-index.htm", "source_name": "SEC.gov", "published_at": "2026-06-06T13:40:48", "published_display": "06 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DWTX - Dogwood Therapeutics Inc Stock Price and Quote", "summary": "This page provides a detailed stock quote and company information for Dogwood Therapeutics Inc (DWTX), including its current stock price, financial metrics, insider and institutional ownership, and recent performance. It also lists significant news events and announcements relate", "url": "https://finviz.com/stock?t=DWTX", "source_name": "Finviz", "published_at": "2026-06-01T23:39:14", "published_display": "01 Jun 2026 23:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Inc. (DWTX) Rises 1.2% as Stock Holds Above Key Support - Volume Breadth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSzlRNGhlOGJXTkxIQzV2eEpBRWxmZG9Fd3BqUWs2Z0lPOXctWW5zQnZlTEhFd3hGbnBCZnVZT2phTFNNMHV3MHJPcWpCenZLZXUwSm5pMWhjWTRSeEhHdWxna0ZKTURjb1ZYZjBKdFh3X0FER3V6WXUxNjluWDFONk93UGtUNmY2MUpfdXJrVmotWXJidVloSlRyVDdVZVpSbmpCVFYzQVBxLTR2UkRlSUw5OE54QUtPSlE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Commencement of Halneuron\u00ae Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-announces-commencement-halneuron-124500058.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:45:00+00:00", "published_display": "18 May 2026 12:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-announces-first-quarter-123000365.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:30:00+00:00", "published_display": "14 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DOGWOOD THERAPEUTICS ($DWTX) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOemVoM1doa2tCRWk3UElHRXpqWmpxR25vY0cxWnQxMGF4bFhkeFVXc0RzX3hFR1piazRZWGFTQ2tlOUQ5YnlLT1lBc2ZCdkg4OVlaMXBtSF9wbzdxbFpOZ0RFQzA4ck9FS2l1RzlCdjNYUUhtZGw5Wi1VcUlRQWhPSl8zTVF6ZWZuV2VRVVZuNHRhX1EyWUZXVg?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-report-first-quarter-123000051.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T12:30:00+00:00", "published_display": "07 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pain-drug developer Dogwood sets May 14 earnings release", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPUkJGZjlhZWh3QzFyeWZYZElhR0JfWjlyVW9ZYU5BWUd6QVNCUVdzT1QycVZvNzFPNFladkNKM3FFOXhhc3RrMUVhZkNHWHdrelNyMFJIaHVybUlDelZqYmphTmZLSU1tTDB4RGxzelVfTEN1OXI5QWdtMlBNTGhXMUk5R09FMlJMOEFkZkFQSmZRNVU4R085LV9zcmVYVTBxenBmeEo1dXVnQnJhQXR1a1RqdFVrNkhZdHk3VjZpYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dogwood-therapeutics-announces-worldwide-development-130000827.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T13:00:00+00:00", "published_display": "23 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Worldwide Development and", "summary": "Dogwood Therapeutics has announced a global development and commercialization partnership with PRIDCor Therapeutics for its anti-viral candidates, IMC-1 and IMC-2, with potential payments of up to $100 million. This agreement allows Dogwood to shift its focus to its lead pain and", "url": "https://www.globenewswire.com/news-release/2026/04/23/3279991/0/en/dogwood-therapeutics-announces-worldwide-development-and-commercialization-partnership-for-anti-viral-assets-with-potential-value-up-to-100m.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T09:00:00", "published_display": "23 Apr 2026 09:00", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood licenses IMC-1, IMC-2 antiviral assets to PRIDCor", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPaDNzUnR0ZDJkQ3JXWktWLS05ZmZRMXBNQ1NSRjlfN1IwRXNhbzJmS1dveWVXYVhzX2FOTXBfVVNzSXBhb0VYcmhMM3Flc2xBSHJKWThianlZYUdjWXJlWnFMUFhpa01jcWxHRW94RWp3R2F5aHROZzhmaHlwdllnVXpuS0g2OWN0YnNNVDluQ0xyTkdoZGY5NDFvN3kzQ29mQnc3aFhnWHgyZ1ZJYXJBUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSGcxQ2t2MTgwV0ZHUWlZc193anZZQnZqZ21VaUp2TnBkZ2hSdWtWQi1fVkVkNlNTQ1lmakhTWVBhTFhNXzdNY0plOHlPWW9HQWcwODFFLTFsMTZvdmlaUzd6T2ctc0dQZEdLSmlaamw3N0xLQlFWQTg0R1FiT2VyaEo1ZWRwdUZ3SE52ZTl3a2kwRHBkQUphOFVqZnZkdTkxLWhiSVhRektIRzQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DWTX - Dogwood Therapeutics Latest Stock News & Market Updates", "summary": "This page provides comprehensive news and analysis for Dogwood Therapeutics (DWTX), a biopharmaceutical company focused on pain and neuropathy treatments. Key updates include the dosing of the first patient in a Phase 2b trial for Halneuron\u00ae for chemotherapy-induced neuropathic p", "url": "https://www.stocktitan.net/news/DWTX/page-3.html", "source_name": "Stock Titan", "published_at": "2026-02-25T18:51:12", "published_display": "25 Feb 2026 18:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics, Inc. Announces Financing of up to", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAJBVV95cUxQa053d29PUVR5TUVwaDNOOEJaU2xzUkU2UmZkLXIxeHNyMWJCRndlU3VleGllUEl0R3pyMG1QaVprSjVqdndJR1pFUGtaY1Y5Y2ZvLTZ5RWVySzhnUFNEOFpmMEFpOUpaOXBXWUF5Mi0xQXVqQmR4VF9vUlZaTXg3REpkekk3VUZ2d3hOUlRGLThGWXlaUVJVSHg1bmtuM3dPQWxxdWtiSW4wZlRYNDdaOGhpSjVEclExeVFpX2JXVlZkMGRXMHhkTUZsQnU4ZlJyRk0wRUlHUUJLR3M3a1RtY3JoNHMzdUJBemlseTlPS2FJZmh3ZlhfdFIwekh6U0RlcjUxTnMwdkdjMU1JdGZndW05NWN6eTV4?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain", "summary": "Dogwood Therapeutics, Inc. today announced positive interim results from its Halneuron\u00ae Phase 2b clinical trial for chemotherapy-induced neuropathic pain (CINP). The interim analysis of 97 patients showed that Halneuron\u00ae treated patients demonstrated separation from placebo in pa", "url": "https://www.globenewswire.com/news-release/2025/12/22/3209363/0/en/dogwood-therapeutics-announces-positive-interim-phase-2b-clinical-trial-results-in-chemotherapy-induced-neuropathic-pain.html", "source_name": "GlobeNewswire", "published_at": "2025-12-22T10:15:00", "published_display": "22 Dec 2025 10:15", "sentiment": "positive", "sentiment_pct": 81, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Reports Third Quarter 2025 Financial Results", "summary": "Dogwood Therapeutics reported its third-quarter 2025 financial results, highlighting significant progress in its clinical trials and pipeline development. The company has enrolled 100 patients in its Halneuron\u00ae Phase 2b trial and secured an exclusive worldwide license for SP16, a", "url": "https://www.globenewswire.com/news-release/2025/11/06/3182625/0/en/Dogwood-Therapeutics-Reports-Third-Quarter-2025-Financial-Results.html", "source_name": "GlobeNewswire", "published_at": "2025-11-06T08:45:00", "published_display": "06 Nov 2025 08:45", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics, Inc. (DWTX) Investor Call Presentation - Slideshow (NASDAQ:DWTX) 202", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNT0JWWkd5OG1tLTd0bGh3XzFOUE5mb3Z3V2l6YkdEa2llb0d2SF9tSVZJZTJtNlZhQ3BjN29kNDlPOXQ4MmdGZFpQY2xFX1BERnRpY1VSdEZDbmg5T1FEY2JibEJwYkRqemZfeTVJZXdEX1V5eF9sRDRQa2hKWDdUSk41S3Bhc3RLcFRncmlzcmp4VkhkajhMVw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-29T07:00:00+00:00", "published_display": "29 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "VIRI SEC Filings - Virios Therapeutics, Inc. 10-K, 10-Q, 8-K Forms", "summary": "This page provides access to SEC filings for Virios Therapeutics (VIRI) and its successor, Dogwood Therapeutics (DWTX), after a business combination with Wex Pharmaceuticals in October 2024. It includes 10-K, 10-Q, 8-K, and Form 4 filings, featuring AI-powered summaries and real-", "url": "https://www.stocktitan.net/sec-filings/VIRI/", "source_name": "Stock Titan", "published_at": "2025-08-13T03:10:34", "published_display": "13 Aug 2025 03:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron\u00ae Phase 2b Trial", "summary": "Dogwood Therapeutics announced the enrollment of the first 50 patients in its ongoing Halneuron\u00ae Phase 2b trial for Chemotherapy-Induced Neuropathic Pain (CINP). The company expects interim data readout for approximately 100 patients in Q4 2025 and plans to release full results i", "url": "https://www.globenewswire.com/news-release/2025/08/07/3129514/0/en/Dogwood-Therapeutics-Announces-Enrollment-of-First-Fifty-Patients-in-Ongoing-Halneuron-Phase-2b-Trial.html", "source_name": "GlobeNewswire", "published_at": "2025-08-07T13:08:00", "published_display": "07 Aug 2025 13:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DWTX Stock: Price, Forecast, Financials & AI Analysis", "summary": "Dogwood Therapeutics, Inc. (DWTX) is a biopharmaceutical company focused on developing therapies for pain and fatigue-related disorders, including a non-opioid analgesic program with Halneuron for cancer pain and an antiviral program. The company has seen significant clinical pro", "url": "https://intellectia.ai/stock/DWTX", "source_name": "Intellectia AI", "published_at": "2025-01-27T09:39:26", "published_display": "27 Jan 2025 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth", "summary": "Virios Therapeutics Llc (DWTX) stock reached a 52-week high of $15.74, showing strong momentum with over 45% growth in the past week, despite being considered overvalued by InvestingPro's Fair Value analysis. The company is facing potential Nasdaq delisting due to low stockholder", "url": "https://www.investing.com/news/company-news/dwtx-stock-hits-52week-high-at-1574-amidst-strong-yearly-growth-93CH-3827837", "source_name": "Investing.com", "published_at": "2025-01-23T12:42:00", "published_display": "23 Jan 2025 12:42", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement", "summary": "Dogwood Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the listing compliance matter. This news comes as the company anticipates top-line results from its Phase 2a study of IMC-2 for Long-COVID in mid-November 2024 and", "url": "https://www.globenewswire.com/news-release/2024/10/30/2971771/0/en/dogwood-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement.html", "source_name": "GlobeNewswire", "published_at": "2024-10-30T21:39:37", "published_display": "30 Oct 2024 21:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dogwood Therapeutics (DWTX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5MUFRfQi11U0xldzg3bXR3WDNieF9IQ1JCZnBVY21KVlItSEl5Mjhnb3A3MmRDRHg1cVNseG5fMTRhY0dpd1FRay1tQ1N2aUdfSm9famdrbXQyQQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-10-12T15:21:14+00:00", "published_display": "12 Oct 2024 15:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors wooed for new analgesic", "summary": "CK Life Sciences is seeking new investors for the continued development of its analgesic drug, Halneuron, following a merger of its biotech subsidiary Wex Pharmaceuticals with US-listed Virios Therapeutics. The new entity, Dogwood Therapeutics, aims to secure incremental funding ", "url": "https://www.thestandard.com.hk/finance/article/66798/Investors-wooed-for-new-analgesic", "source_name": "The Standard (HK)", "published_at": "2024-10-09T11:10:45", "published_display": "09 Oct 2024 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CK Life unit to merge with Nasdaq biotech", "summary": "CK Life Sciences International announced that its wholly-owned subsidiary will merge with Nasdaq-listed Virios Therapeutics. The combined entity, to be renamed Dogwood Therapeutics, will remain listed on Nasdaq. This strategic move involves CK Life selling Pharmagesic to Virios f", "url": "https://www.thestandard.com.hk/finance/article/66751/CK-Life-unit-to-merge-with-Nasdaq-biotech", "source_name": "The Standard (HK)", "published_at": "2024-10-08T11:41:44", "published_display": "08 Oct 2024 11:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics Transforms into Dogwood Therapeutics", "summary": "Virios Therapeutics has announced its merger with Pharmagesic, a subsidiary of Sealbond Limited, resulting in the formation of Dogwood Therapeutics, Inc. The newly branded company will focus on developing non-opioid pain treatments and antiviral drugs for long-term health conditi", "url": "https://finance.yahoo.com/news/virios-therapeutics-transforms-dogwood-therapeutics-122907415.html", "source_name": "Market source", "published_at": "2024-10-08T03:51:57", "published_display": "08 Oct 2024 03:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics And Wex Pharmaceuticals To Merge", "summary": "Virios Therapeutics and Wex Pharmaceuticals have announced a definitive share exchange agreement to merge in an all-stock transaction, forming Dogwood Therapeutics, Inc. (NASDAQ: DWTX). The combined company will focus on developing three assets: Halneuron\u00ae for chemotherapy-induce", "url": "https://www.citybiz.co/article/609380/virios-therapeutics-and-wex-pharmaceuticals-to-merge/", "source_name": "citybiz", "published_at": "2024-10-07T22:09:34", "published_display": "07 Oct 2024 22:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: \u201cDWTX\u201d)", "summary": "Virios Therapeutics and Wex Pharmaceuticals have announced a business combination to form Dogwood Therapeutics, Inc. (NASDAQ: DWTX). This new company will focus on developing three assets: Halneuron\u00ae for chemotherapy-induced neuropathic pain, IMC-1 for fibromyalgia, and IMC-2 for", "url": "https://finance.yahoo.com/news/virios-therapeutics-inc-wex-pharmaceuticals-110500914.html", "source_name": "Market source", "published_at": "2024-10-07T17:27:32", "published_display": "07 Oct 2024 17:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc.", "summary": "Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. are combining to form Dogwood Therapeutics, Inc. (Nasdaq: DWTX), focusing on developing treatments for chemotherapy-induced neuropathic pain, fibromyalgia, and Long-COVID. The new company secured $19.5 million in financing a", "url": "https://www.globenewswire.com/news-release/2024/10/07/2958810/0/en/virios-therapeutics-inc-and-wex-pharmaceuticals-inc-announce-business-combination-to-form-dogwood-therapeutics-inc-nasdaq-dwtx.html", "source_name": "GlobeNewswire", "published_at": "2024-10-07T07:05:00", "published_display": "07 Oct 2024 07:05", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 46, "sentiment_summary": {"positive": 11, "negative": 3, "neutral": 32, "score": 56, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 11.9, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 1.42, "latest_week": "2026-07-10", "one_week_move": -4.7, "four_week_move": -7.8, "twelve_week_move": -14.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.294742, "market_dynamics_buy_signal": false, "relative_strength": -68.250608, "fair_value_gap": -82.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.3108, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.7% over one week, -7.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 12}, {"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "TradingView", "count": 2}, {"label": "Donan\u0131mHaber", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "The Standard (HK)", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 18}, {"label": "Deals and strategy", "count": 4}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.7% over one week, -7.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to sales forward of Dogwood Therapeutics, Inc. \u2013 NASDAQ:DWTX"}], "updated_at": "2026-07-17T09:58:59.478738+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}